FDA To Meet With Medtronic On Drug Pump Risks; Warning Letter Sent

The agency posted a warning letter to Medtronic Aug. 21 citing the firm for multiple quality system deviations, including lapses in its efforts to address a failure risk for the SynchroMed II drug infusion pump.